Warning: SNY is at high risk of cutting its dividend
https://seekingalpha.com/warnings/4052831-warning-sny-is-high-risk-of-cutting-dividend?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
Jan 07, 2024 - Sanofi (NASDAQ:SNY) has displayed warning signs that have historically led to dividend cuts. The company has a Dividend Safety Score of F.
0
Sanofi (SNY) Presents at J.P. Morgan 42nd Annual Healthcare Conference Call Transcript
https://seekingalpha.com/article/4662029-sanofi-sny-presents-j-p-morgan-42nd-annual-healthcare-conference-call-transcript?source=feed_sector_transcripts
Jan 09, 2024 - Sanofi (NASDAQ:NASDAQ:SNY) J.P. Morgan 42nd Annual Healthcare Conference Call January 9, 2024 1:30 PM ETCompany ParticipantsPaul Hudson - Chief Executive...
0
3 Stocks to Buy Before 2024 That Can Set You Up For Life
https://www.fool.com/investing/2023/12/14/3-stocks-to-buy-before-2024-that-can-set-you-up/?source=iedfolrf0000001
Dec 14, 2023 - These stocks are still relatively cheap, but don't expect them to stay that way for long.
0
Sanofi (SNY) Q4 2023 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/02/01/sanofi-sny-q4-2023-earnings-call-transcript/?source=iedfolrf0000001
Feb 01, 2024 - SNY earnings call for the period ending December 31, 2023.
0
Sanofi (SNY) Q1 2024 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/04/25/sanofi-sny-q1-2024-earnings-call-transcript/?source=iedfolrf0000001
Apr 25, 2024 - SNY earnings call for the period ending March 31, 2024.
0
Sanofi (SNY) Posts Upbeat Long-Term Outlook, Enhances R&D Focus
https://www.zacks.com/stock/news/2195113/sanofi-sny-posts-upbeat-long-term-outlook-enhances-r-d-focus?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195113
Dec 07, 2023 - Sanofi (SNY) aims to generate annual sales of over 10 billion euros by 2030, driven by recently launched and potential new products. It intends to enhance R&D focus to become a market leader in immunology.
0
AstraZeneca (AZN) to Acquire Vaccine Maker Icosavax for $1.1B
https://www.zacks.com/stock/news/2196741/astrazeneca-azn-to-acquire-vaccine-maker-icosavax-for-1-1b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196741
Dec 12, 2023 - AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Icosavax, for a total deal value of up to $1.1 billion.
0
Sanofi (SNY) Terminates Pompe Disease Deal as FTC Objects
https://www.zacks.com/stock/news/2196713/sanofi-sny-terminates-pompe-disease-deal-as-ftc-objects?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196713
Dec 12, 2023 - Sanofi (SNY) decides to end the licensing deal with Maze Therapeutics for MZE001, a phase II ready oral tablet for Pompe disease, due to the FTC's decision to block the deal.
0
Top Analyst Reports for Alphabet, Comcast & NextEra Energy
https://www.zacks.com/commentary/2201007/top-analyst-reports-for-alphabet-comcast-nextera-energy?cid=CS-ZC-FT-research_daily-2201007
Dec 21, 2023 - Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Comcast Corp. (CMCSA) and NextEra Energy, Inc. (NEE).
0
Pharma Stock Roundup: LLY's New Digital Pharmacy, NVO & ABBV's Fresh R&D Deals
https://www.zacks.com/stock/news/2206363/pharma-stock-roundup-lly-s-new-digital-pharmacy-nvo-abbv-s-fresh-r-d-deals?cid=CS-ZC-FT-analyst_blog|stock_roundup-2206363
Jan 05, 2024 - Eli Lilly (LLY) launches a new direct-to-consumer website to provide easy access to its medicines. Novo Nordisk (NVO) announces two research collaborations to develop novel treatments for cardiometabolic diseases.
0
Page 1>